Tradeline, Inc. filters and categorizes new-construction and industry news from regional and professional journals across the country. Here you will find new projects, products, and regulatory updates.
Industry News
Kent State University Will Offer High Level Biosafety Training
The National Biosafety and Biocontainment Training Program will offer biosafety training in Kent State University’s Cunningham Hall in Ohio. Providing education for professionals working in BSL-3 and BSL-4 laboratories, the facility is the second location in the country to provide training in high level biocontainment operations.
Georgia Southern University Builds Biocontainment Lab
Georgia Southern University is constructing the Public Health Core Research Lab in Statesboro. Part of the Jiann-Ping Hsu College of Public Health, the facility is comprised of two BSL-3 research labs, two teaching labs, and two chemistry labs. Completion is expected in 2010.
Canadian Science Centre for Human and Animal Health Initiates Expansion
The Canadian Science Centre for Human and Animal Health is initiating a $16.5 million expansion and renovation of its Winnipeg research facility. Designed by Smith Carter and built by PCL Constructors, the project includes a 1,600-sm, three-story laboratory addition and infrastructure upgrades to the National Microbiology Laboratory and the National Centre for Foreign Animal Disease. Completion is expected by March of 2011.
Haffkine Institute Builds BSL-3 Lab
The Haffkine Institute is installing a pre-fabricated BSL-3 laboratory in Parel, Mumbai. Created by M+W Zander, the facility will support infectious disease testing for HINI, avian influenza, and other zoonotic agents. The laboratory will include biosafety cabinets, advanced air filtration, and a dedicated effluent decontamination system.
SAFC Pharma Opens BSL-2 Facility
SAFC Pharma completed the expansion of its $12 million contract manufacturing facility in October of 2009. Located in Carlsbad, Calif., the BSL-2 project features two fully segregated viral product manufacturing suites. Utilizing disposable bioreactor technologies, the expansion will enable SAFC Pharma to produce biologics, viral vaccines, and gene therapies in commercial-scale quantities. The facility includes dedicated cell expansion, bioreactor production, purification, and cleanroom suites. The project added 8,000-sf to the existing 44,000-sf building.